Imatinib is the mainstay of treatment of patients with chronic myeloid leukemia (CML) in Tanzania. Monitoring molecular response to therapy by real-time polymerase chain reaction at defined milestones is necessary for early detection of treatment failure. However, this assay is not routinely performed in Tanzania; therefore, the depth of molecular response among patients with CML is not known. A total of 158 patients with previously diagnosed CML who received imatinib treatment were recruited from January 2019 and followed up through October 2020 at Ocean Road Cancer Institute. Information was obtained at the time of diagnosis and follow-up. Blood samples were collected in EDTA tubes to measure the BCR/ABL ratio on the Gene Xpert system for molecular response determination. The median age of the 158 adult patients was 45 years (range, 18-86). By reference to established treatment milestones, only 37 (23.4%) achieved optimal molecular response. Signs of advanced-stage disease, in particular the need for red cell transfusions before diagnosis (adjusted odds ratio [AOR], 3.4; 95% CI, 1.32-9.17) and cytopenias (AOR, 2.26; 95% CI, 1.03-4.96) necessitating drug interruptions were statistically validated predictors of treatment failure on multivariate, multinomial logistic regression. Patient survival at the 22-month follow-up was lowest, with 78.6% (95% CI, 69.4-85.4) in the failure-to-respond category and highest in patients achieving optimal response 97.0% (95% CI, 80.9-99.6). In summary, the majority of patients with CML treated with imatinib in Tanzania do not obtain deep molecular response. This outcome can be attributed to late diagnosis, the development of cytopenias requiring multiple drug interruptions, and poor adherence to treatment.
Burkitt lymphoma (BL) has a cure rate of around 95% when treated with chemoimmunotherapy that is standard of care in high-income countries (Minard-Colin et al., 2020, New England Journal of Medicine 382, 2207-2219), but currently, more than 50% of children and young adults with endemic BL (Epstein Barr virus driven BL) in sub-Saharan Africa (SSA) do not survive. Treatment for BL is largely free of charge, but there is limited access to reliable diagnostic services leading to significant delays and misdiagnoses. Innovations in histopathology such as whole slide imaging and the use of novel diagnostic approaches, in particular using circulating cell-free viral and/or lymphoma DNA (liquid biopsy), could increase access to timely and reliable diagnosis and improve outcomes in SSA. Impact statement Burkitt lymphoma (BL) is a highly aggressive but curable cancer that commonly affects children. The current diagnostic pathway for BL is tissue biopsy. This is an invasive procedure that requires highly skilled personnel and specialised equipment, both of which are in short supply in sub-Saharan Africa (SSA). This results in diagnostic delays which can be as long as 2 months from the time the patient present to hospital. As a result of the highly aggressive nature of this cancer, late presentation and the diagnostic delays with tissue biopsy, the majority of children die before receiving a diagnosis. Clinicians are at times compelled to treat children based on clinical suspicion, or the less recommended method of fine needle aspiration cytology, which usually results in misdiagnosis and initiation of the wrong treatment. In our article, we highlight the need to look beyond the traditional/common methods that are used in routine clinical practice to diagnose BL and leapfrog into the advanced alternative method of 'liquid biopsy', which may be potentially faster and more precise and curb the existing diagnostic challenges. We discuss the possible implementation of this technology in SSA in view of the existing technical and infrastructural challenges that need to be considered.
Introduction. Anaemia is a common problem in sub-Saharan Africa. While most literature has focused on children, women of childbearing age, and pregnant women, data for the elderly population are relatively scarce. Anaemia exhorts negative consequences to functional ability of elderly patients, both physically and cognitively. The purpose of this study was to determine the prevalence of anaemia, severity, and micronutrient deficiency status in the elderly hospitalized patients in Tanzania. Methods. A total of 156 hospitalized adults aged 60 years and above were enrolled in this study. A structured questionnaire was used to capture sociodemographic and clinical characteristics. Blood samples were collected, and a complete blood count, serum cobalamin, serum ferritin, and serum folate levels were measured to assess anaemia and micronutrient deficiency status in all participants who had anaemia. Results. The prevalence of anaemia was 79.5 (124/156) with severe anaemia in 33.9 (42/124) of participants, moderate anaemia in 42.7 (53/124) of participants, and 23.4 (29/124) of all participants had mild anaemia. Micronutrient deficiency was found in 14.5 (18/124) of all participants with anaemia. Combined deficiency (either iron and vitamin B12 deficiency or iron and folate deficiency) was the most common micronutrient deficiency anaemia with a frequency of 33.3 (6/18), followed by isolated iron and folate deficiencies at equal frequency of 27.8 (5/18) and vitamin B12 deficiency at 11.1 (2/18). Conclusion. The prevalence of anaemia in the hospitalized elderly population is high warranting public health attention and mostly present in moderate and severe forms. Micro-nutrient deficiency anaemia is common in this age group and is mostly due to combined micronutrient deficiency.